New blood thinner tested in small chinese heart study
NCT ID NCT07615868
First seen Jun 25, 2026 · Last updated Jul 15, 2026 · Updated 3 times
Summary
This early-stage trial will study how a single 16 mg dose of selatogrel, an injectable blood thinner, is absorbed and tolerated in 20 Chinese adults with chronic coronary syndrome. Participants will stay at a clinic for a few days and receive either selatogrel or a placebo. The goal is to gather safety and drug-level data, not to treat the condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- selatogrel
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC CORONARY SYNDROME are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Anzhen Hospital
RECRUITINGBeijing, 100029, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a higher dose of adenosine sharpen heart scans?
- Can a trained eye match ultrasound for heart stent placement?
- Could a quicker, cheaper scan replace the gold standard for heart blood flow?
- Could a neck ultrasound replace heart CT scans for chest pain patients?
- Fish oil derivative may calm heart inflammation and stabilize plaques
- Heart stent mystery: new diagnostic strategy could reveal hidden causes of Post-PCI angina